Miguel Mesa-Guzman
Overview
Explore the profile of Miguel Mesa-Guzman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodrigo V, Corral P, Mesa-Guzman M, Perna V, Rosenthal D, Fernandez R
World Neurosurg
. 2024 Sep;
192:59-62.
PMID: 39270788
Objective: This work aims to describe the evolution of the video-assisted Thoracoscopic Surgery (VATS) approach from a multiportal access to a biportal access for thoracic herniated disc surgery. Thoracic disc...
2.
Felberg A, Bienkowski M, Stokowy T, Myszczynski K, Polakiewicz Z, Kitowska K, et al.
Transl Res
. 2024 Feb;
269:1-13.
PMID: 38395390
While numerous membrane-bound complement inhibitors protect the body's cells from innate immunity's autoaggression, soluble inhibitors like complement factor I (FI) are rarely produced outside the liver. Previously, we reported the...
3.
Khodayari Moez E, Warkentin M, Brhane Y, Lam S, Field J, Liu G, et al.
J Natl Cancer Inst
. 2023 Jun;
115(9):1060-1070.
PMID: 37369027
Background: Although lung cancer screening with low-dose computed tomography is rolling out in many areas of the world, differentiating indeterminate pulmonary nodules remains a major challenge. We conducted one of...
4.
Rodriguez M, Ajona D, Seijo L, Sanz J, Valencia K, Corral J, et al.
Transl Lung Cancer Res
. 2021 Mar;
10(2):1165-1185.
PMID: 33718054
Low dose computed tomography (LDCT) screening, together with the recent advances in targeted and immunotherapies, have shown to improve non-small cell lung cancer (NSCLC) survival. Furthermore, screening has increased the...
5.
Ajona D, Remirez A, Sainz C, Bertolo C, Gonzalez A, Varo N, et al.
Transl Res
. 2021 Feb;
233:77-91.
PMID: 33618009
Lung cancer screening detects early-stage cancers, but also a large number of benign nodules. Molecular markers can help in the lung cancer screening process by refining inclusion criteria or guiding...
6.
Aguado C, Teixido C, Roman R, Reyes R, Gimenez-Capitan A, Marin E, et al.
Mol Oncol
. 2020 Nov;
15(2):350-363.
PMID: 33236532
MET inhibitors have shown activity in non-small-cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied...
7.
Martinez-Terroba E, Behrens C, de Miguel F, Agorreta J, Monso E, Millares L, et al.
J Pathol
. 2018 May;
245(4):421-432.
PMID: 29756233
Each of the pathological stages (I-IIIa) of surgically resected non-small-cell lung cancer has hidden biological heterogeneity, manifested as heterogeneous outcomes within each stage. Thus, the finding of robust and precise...
8.
Mesa-Guzman M, Periklis P, Niwaz Z, Socci L, Raubenheimer H, Adams B, et al.
J Thorac Dis
. 2015 Dec;
7(11):2053-7.
PMID: 26716045
Background: Chest drain duration is one of the most important influencing aspects of hospital stay but the management is perhaps one of the most variable aspects of thoracic surgical care....